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Growing evidence suggests drugs that can activate the glucagon-like peptide 1 receptor can
modulate several pathological processes underlying Parkinson’s disease. Here, we review the
molecular mechanisms underlying these potential neuroprotective effects.
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Growing evidence suggests that agonists of the glucagon-like peptide 1
(GLP-1) receptor provide neuroprotection across a range of experimental
models of Parkinson’s disease (PD) and, recently, a small proof-of-concept,
open-label human trial of exenatide in the treatment moderate severity PD
appeared to show persistent improvements in motor and cognitive
function. The underlying mechanisms of action remain unclear, but as
evidence for the potential use of GLP-1 agonists in treating several
neurodegenerative disease mounts, and with several clinical trials of GLP-1
analogues in PD and Alzheimer’s disease (AD) currently underway, here we
review the molecular mechanisms underlying the neuroprotective effects
of GLP-1 analogues in the laboratory and their potential therapeutic utility
with particular relevance to PD and PD dementia (PDD).
Introduction
Parkinson’s disease (PD) is the second most common neurodegenerative disease and affects 1.5%
of humans over 65 years of age globally. Current treatments are aimed at dopamine (DA)
replacement and, although these treatments can initially be effective in relieving motor symp-
toms, over time complex motor fluctuations and dyskinesias can occur, which negatively impact
patients’ quality of life and mobility. Although more advanced therapies, including continuous
intraduodenal infusion of levodopa, subcutaneous apomorphine infusions, and deep brain
stimulation, have varying levels of success at minimising these motor complications, they
ultimately have no effect on altering the progressive nature of the disease. Furthermore, over
time, the involvement of nondopaminergic systems influences the onset of features such as
depression, gait difficulties, and dementia, which are often refractory to treatment and have
profound effects on patients’ quality of life. Therefore, an urgent goal is to develop effective
neuroprotective treatments that target pathways common to neurodegeneration and affect both
dopaminergic and nondopaminergic systems and, therefore, that could slow the progression of
the disease.
The incretin hormone glucagon-like peptide 1 (GLP-1) is best known for its effects on glucose
homeostasis and facilitation of insulin signalling and, as such, agents that activate the GLP-1
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Amyloid beta (Ab) peptides of 36–43 amino acids that are
the main component of the amyloid plaques found in the
brains of patients with AD.
Alpha-synuclein a major component of Lewy bodies, the
pathological correlate found in the brains of patients with PD.
Insulin resistance a condition describing the reduced
responsiveness of cells to the action of insulin.
Insulin receptor substrate 1 (IRS-1) a critical component of
intact insulin signalling; phosphorylation of IRS-1 on serine
residues prevents insulin/IGF-1 binding to the IR and
subsequent activation of downstream effectors.
Microglial cells resident macrophages in the CNS that
mediate a balance between neuroprotection and
neurotoxicity; when activated, they can express a
cytoprotective M2 phenotype generally providing trophic
support and inhibiting inflammation; however, continuous
exposure to stress and prolonged microglial activation can
lead to polarisation towards the cytotoxic M1 phenotype,
causing production of superoxide proinflammatory cytokines
that leads to progressive oxidative stress cell death.
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Wreceptor (GLP-1R), such as GLP-1 analogues or dipeptidyl pepti-
dase 4 (DPP-IV) inhibitors, have been developed for use in the
treatment of type 2 diabetes mellitus (T2DM). Accumulating evi-
dence suggests that these GLP-1 analogues exert several extrapan-
creatic effects independent of glucose homeostasis and can cross
the blood–brain barrier (BBB) to influence several cellular path-
ways, such as neuroinflammation, mitochondrial function, and
cellular proliferation, within the central nervous system (CNS).
Furthermore, a growing number of studies have demonstrated
neuroprotective effects of GLP-1 R stimulation in models of PD,
resulting in improvements in motor and non-motor deficits.
The neuropathophysiology underlying cognitive decline in PD
remains unclear, although deposition of Lewy body-related pa-
thology in neocortical and limbic areas is thought to represent one
of the most significant factors. However, accumulating evidence
suggests that Alzheimer’s disease (AD)-type pathology is undoubt-
edly relevant for at least a subset of individuals with PD dementia
(PDD) due to either superimposed AD-type pathology, or because
of an interaction between amyloid b (Ab) and the rate of progres-
sion of cortical Lewy body and/or alpha synuclein pathology [1].
In this review, we discuss the effects of GLP-1R stimulation with
respect to PD and, where relevant, the evidence emerging from
research into GLP-1 stimulation and AD-related pathology. We
then follow by reviewing the proposed mechanisms underlying its
effects.
The GLP-1 signalling pathway
GLP-1 is an endogenous 30 amino-acid multifunctional peptide
first recognised for its role in mediating the ‘incretin’ effect.
Secreted from L cells in the small intestine in response to food
ingestion, it stimulates glucose-induced insulin secretion, insulin
biosynthesis, slows gut emptying, and inhibits glucagon secretion,
to mediate glucose homeostasis. In additional to its metabolic
effects, it also exerts trophic effects, namely enhancing islet beta
cell proliferation differentiation, inhibiting apoptosis, and en-
hancing cell survival, thus regulating B cell mass [2,3].A small amount of GLP-1 is also produced in the brain, released
from hypothalamic nuclei from nerve endings with cell bodies in
the nucleus of the solitary tract and caudal brainstem that project
to cortical, hypothalamic, and hippocampal nuclei. In its role as a
neuropeptide, GLP-1 can diffuse within the brain to regulate many
autonomic and neuroendocrine functions, including promoting
satiety, pancreatic secretions, slowing gastric emptying, and regu-
lating blood pressure and heart rate [4].
The actions of GLP-1 are mediated by GLP-1R, a seven-trans-
membrane spanning G-protein-coupled receptor (GPCR) that,
although mainly expressed in pancreatic islets, is also selectively
expressed throughout the brain, with high densities in the frontal
cortex, hypothalamus, thalamus, hippocampus, cerebellum, and
substantia nigra [5,6]. Similar to islet cells that can upregulate GLP-
1 expression under stressful conditions, such as T2DM [7], it was
recently demonstrated that microglial cells can also increase GLP-1
and GLP-1R expression in response to inflammatory stimuli [8],
suggesting that endogenous GLP-1 is a natural response to limit
harmful stimuli.
Following activation of the alpha subunit of the GPCR, adenyl
cyclase is activated, leading to an increase in intracellular cAMP,
which then activates protein kinase A (PKA) and phosphoinositide
3-kinase (PI3K), which phosphorylates and activates a variety of
downstream signalling pathways. These pathways can be simpli-
fied into two branches: (i) the mitogen-associated protein kinase/
extracellular signal-regulated kinase (MAPK/ERK; also known as
Ras-Raf-MEK-ERK); and (ii) PI3K/protein kinase B (AKT) pathways
[9]. An important downstream target of GLP-1 signalling is the
AKT pathway, which acts as a major regulator of physiological
responses to normal ageing. AKT has the ability to phosphorylate
over 50 substrate proteins, such as glycogen synthase kinase 3 beta
(GSK-3B), Forkhead box protein O1 (FOXO1), and mammalian
target of rapamycin (mTOR), and can modulate several cellular
processes found to be disrupted in PD, such as protein synthesis,
apoptosis, inflammation, mitochondrial biogenesis, and autop-
hagy. Broadly speaking, activation of these pathways promotes
cellular survival, while inhibiting proapoptotic pathways (Fig. 1).
Further details of the relation between these processes and PD
pathogenesis are discussed in subsequent sections of this article.
Unfortunately, endogenous GLP-1 is rapidly rendered inactive
by circulating enzyme dipeptidyl peptidase IV (DPP-IV) into a
metabolite that has no activity against GLP-1R [10–12]. However,
the discovery of a naturally occurring GLP-1 agonist resistant to
DPP-IV degradation, named exendin-4, in the saliva of the Gila
monster (Heloderma suspectum), a venomous lizard native to the
south-western USA and Mexico, has allowed researchers to cir-
cumvent this obstacle. Subsequently, synthetic versions of exen-
din-4 and several other GLP-1 analogues have since been
developed [13] for use in diabetes to utilise their insulinotrophic
actions and include exenatide, liraglutide, lixisenatide, and dula-
glutide. These GLP-1 analogues have significantly longer half-lives
than endogenous GLP-1 and exert a dose-dependent pharmaco-
logical effect that can raise circulating levels of endogenous GLP-1
levels eightfold [14]. Apart from dulaglutide, these peripherally
administered drugs are all also able to penetrate the BBB to some
degree in experimental models [15,16] to exert central effects.
Representing an alternative approach to GLP-1R stimulation,
orally administered drugs have been developed more recently thatwww.drugdiscoverytoday.com 803
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FIGURE 1
Glucagon-like peptide 1 (GLP-1) receptor activation in neurons showing the influence of downstream pathways on Parkinson’s disease (PD) pathogenesis.
Stimulation of the GLP-1 receptor (GLP-1R) leads to an increase in intracellular cAMP, which then activates protein kinase A (PKA) and phosphoinositide 3-kinase
(PI3K), which phosphorylate and activate a variety of downstream signalling pathways that can be simplified into two branches: the mitogen-associated protein
kinase/extracellular signal-regulated kinase (MAPK/ERK; also known as Ras-Raf-MEK-ERK) and PI3K/protein kinase B (AKT) pathways, which can modulate
intracellular events, such as activation of calcium channels, enhancing protein synthesis, cellular proliferation, and mitochondrial biogenesis while inducing
inhibition of apoptosis, inflammation, and protein aggregation, leading to improved cell survival. Abbreviations: Bcl-2, B cell lymphoma 2; BAD, (Bcl-2) antagonist of
death; Bcl-XL, B cell lymphoma 2 extra-large; cAMP, cyclic AMP; CREB, cAMP response element-binding protein; FoxO1/O3, Forkhead box O1/O3; GSK-3B, glycogen
synthase 3 beta; LTP, long-term potentiation; mTOR, mammalian target of rapamycin; NF-kB, nuclear factor kappa-light-chain-enhancer of activated B cells; TNF,
tumour necrosis factor.
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twofold. This class of drugs is currently used an adjunctive therapy
in diabetes and includes sitagliptin, saxagliptin, vildagliptin, and
linagliptin.
GLP-1R activation in models of PD and AD
In view of the influence that GLP-1R activation has on diverse
cellular processes, it is perhaps not surprising that accumulating
data indicate that agents that can activate GLP-1R have potential
neuroprotective and neurorestorative properties across a range of
experimental models of PD and AD (Tables 1 and 2). In widely used
animal toxin models designed to mimic aspects of nigrostriatal
degeneration seen in PD, exenatide-treated animals can halt 6-
OHDA, MPTP, and lipopolysaccharide (LPS)-induced dopaminer-
gic degeneration and restore DA imbalance, resulting in significant
improvements in behaviour and motor function [17–20]. Interest-
ingly, exenatide was also able to restore levels of other neuro-
transmitters depleted in PD. In a novel rodent model with804 www.drugdiscoverytoday.comdopaminergic, serotonergic, and noradrenergic deficits, exenatide
administration restored levels of these neurotransmitters, leading
to a reversal of neuropsychiatric dysfunction [21]. Similarly, newer
GLP-1 analogues with longer half-lives (liraglutide and lixisena-
tide) have also demonstrated protective effects and improved
motor function in the MPTP rodent model of PD [22].
However, data from DPP-IV inhibitors in experimental models
of PD are conflicting. Rats pretreated with saxagliptin before the
induction of rotenone-induced nigrostriatal lesions demonstrated
enhanced striatal DA synthesis and reduced dopaminergic neuro-
nal loss, resulting in improved motor performance and coordina-
tion in a rotarod test [23]. However, rats acutely or chronically
pretreated with supramaximal doses of sitagliptin (a DPP-IV in-
hibitor with a substantially longer half-life than saxagliptin) were
not protected against MPTP-induced striatal dopaminergic degen-
eration [24].
GLP-1 analogues have also been studied in experimental models
of AD for their effects on AD-related pathology and cognition. Use
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TABLE 1
Effects of GLP-1 analogues and DPP-IV inhibitors in models of PD: data from experimental models and clinical trials
Drug Experimental data Results and/or effects Human data Refs
GLP-1 analogue
Exenatide In vitro PC12 cells Promoted NGF-initiated differentiation;
rescued degenerating cells after NGF-
mediated withdrawal
Open-label RCT in 45 patients which led to a
mean advantage of 7.0 points on MDS-UPDRS
Part III, which persisted after a 12-month
‘wash-out’ period, together with
improvements in Mattis Dementia Rating
scale and other non-motor areas [240,241];
Phase II double-blind, placebo controlled trial
underway (Clinicaltrials.gov NCT01971242)
[157]
In vitro 6-OHDA Increased number of TH+ striatal neurons;
elevated antiapoptotic proteins Bcl-2;
reduced expression proapoptotic proteins
caspase-3 and Bax
[16]
Rat LPS Post-lesioning treatment restored depletion
of extracellular DA and TH activity back to
normal levels, increased striatal tissue DA
concentrations and number of nigral TH+
neurons, reduced apomorphine-induced
rotations
[15]
Rat 6-OHDA Post-lesioning treatment protected DA
neurons, increased striatal tissue DA
concentrations and number of nigral TH+
neurons, reduced apomorphine-induced
rotations
[15]
Mouse MPTP Prelesioning treatment preserved TH+
neurons and preserved motor function in
rotarod and pole tests indistinguishable from
controls
Mouse MPTP Prelesioning treatment reduced loss of TH+
striatal neurons, halted microglial activation
and MPTP-induced expression of matrix
metalloproteinase 3, TNF-a and IL1b
[18]
Rat 6-OHDA Increased the number of TH- and VMAT2-
positive neurons in the SN, increased and
normalised amphetamine-induced rotations
[17]
Novel rodent model with
NA, SA and DA deficits
Post-lesioning treatment restored
extracellular/tissue levels of DA, NA and SA
and TH+ cell counts; reversed
neuropsychiatric dysfunction
[19,249]
Liraglutide Mouse MPTP Post-lesioning treatment preserved TH+
neurons in the SN; reduced levels of BAX and
increased Bcl-2; prevented motor impairment
in rotarod, open-field locomotion, catalepsy
tests
No human data currently [20]
Lixisenatide Mouse MPTP Post-lesioning treatment preserved TH+
neurons in the SN; reduced levels of BAX and
increased Bcl-2; prevented motor impairment
in rotarod, open-field locomotion, catalepsy
tests
No human data currently [22]
Dulaglutide No experimental data No experimental data currently No human data currently
DPP-IV inhibitor
Saxagliptin Rat rotenone Preserved SNPc TH+ neurons; decreased NF-
kB, iNOS, TNF-a, ICAM-1, MPO, capase-3,
increased Bcl-2, BDNF
No human data currently [21]
Sitagliptin Mouse MPTP Did not prevent DA degeneration, TH
depletion
No human data currently [22]
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related pathology and cognition, causing reductions in deposition
of Ab, and Ab-induced proinflammatory responses, enhancing
synaptic plasticity, hippocampal neurogenesis, and long-term
potentiation (LTP), translating to improvements in cognitive def-
icits [25–33].
However, studies using DPP-IV inhibitors have somewhat con-
flicting results. Saxagliptin and sitagliptin administration caused
an increase in hippocampal GLP-1 levels in rodents injected withintracerebral streptozotocin and transgenic (Tg) AD mice, respec-
tively, accompanied by reduction in AD-related pathology and
inflammatory markers and improvements in memory impair-
ments [34,35]. However, in diabetic rats and primary cortical
neurons, sitagliptin administration caused a paradoxical increase
in tau phosphorylation [36].
Despite the range of neuroprotective effects seen in various
models, there remains an amount of mechanistic uncertainty
regarding the downstream effects of GLP-1R activation. However,www.drugdiscoverytoday.com 805
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TABLE 2
Effects of GLP-1 analogues and DPP-IV inhibitors in models of AD: data from experimental models and clinical trials
Drug Experimental model Results and/or effects Human data Refs
GLP-1 analogue
Exenatide 3  Tg-AD mice with and
without STZ-induced diabetes.
Protected neurons from Ab oxidative-
induced cell death, lowered brain levels of
APP and Ab in vivo; tau levels unaffected
Phase II trial evaluating
exenatide in 230 patients with
AD or MCI (NCT01255163) is
underway
[29]
ICV-STZ rats Reversed ICV-STZ-induced tau
hyperphosphorylation leading to better
learning and memory performance in Morris
water maze test
[110]
PC12 cells treated with glucose-
bovine serum albumin (BSA)
Protected neurons: reduced cell tau
phosphorylation induced by high glucose
[112]
T2DM rats Prevented hyperphosphorylation of tau in
hippocampus and improved insulin signalling
[109]
In vitro hippocampal neurons and
mice
Reduced levels of Ab in brain in vivo; reduced
levels of APP in cell cultures
[28]
Hippocampal rat neurons; APP/
PSEN1 mutant mice; Ab
oligomer-induced toxicity in
nonhuman primates
Neurons: prevented Ab oligomer-induced
increase in IRS-1pSer, improving impaired
axonal transport; Tg mice: reduced brain
levels of IRS-1pSer636, IRS-1pSer312, and
pJNK, with an improvement in cognition
[201]
Liraglutide T2DM mice Reversed DM-induced brain and peripheral
insulin sensitivity, halted tau
hyperphosphorylation
Randomised, placebo-
controlled Phase II trial
assessing safety and efficacy
of liraglutide in 206 patients
with early AD (NCT018430755)
is underway; trial assessing
effects of liraglutide on
cerebral amyloid deposits
(NCT01469351) is underway;
pilot trial of liraglutide in
patients with DLB is in
planning stages
[114]
ICV-STZ mice Decreased hyperphosphorylation of tau and
neurofilament proteins; improved learning
and memory ability
[250]
Senescence-accelerated mouse
prone 8 (SAMP8) mice
Delayed progressive decline in memory
function; increased memory retention and
total hippocampal CA1 pyramidal neurons
[139]
Db/db mice Prevented hyperphosphorylation of tau
protein in hippocampus
[113]
7-month-old APP/PSEN1 mice Prevented memory impairments in object
recognition and water maze tasks; reduced
synapse loss; reduced amyloid and dense
core plaque load; reduced microglial
activation
[61]
Ab oligomer-induced toxicity in
rats
Improved spatial learning and memory water
maze tests; improved LTP in hippocampal
CA1 region
[26]
Decreased levels of IRS-1pS616; reduced
microglial activation; decreased amyloid
plaque load
[202]
14-month-old APP/PSEN1 mice Improved spatial memory; reduced total
brain APP and Ab levels; increased IDE levels;
increased neuronal progenitor cells and/or
synapses in dentate gyrus
[251]
2-month-old APP/PSEN1 mice Prophylactic treatment improved memory
formation in Morris water maze; prevented
synapse loss; reduced amyloid plaque load,
including dense core congophilic plaques;
reduced activated microglia; enhanced
neurogenesis in dentate gyrus
[252]
Lixisenatide APP/PSEN1 mice Increased LTP; prevented synapse loss;
reduced amyloid plaque load; reduced
microglial activation
[253]
Ab oligomer-induced toxicity in
rats
Prevented Ab-induced decline in spatial
learning; improved LTP
[252]
DPP-IV inhibitor
Saxagliptin ICV-STZ mice Halted Ab, tau phosphorylation; reduced
inflammatory markers; elevated hippocampal
GLP-1; improved memory retention
[32]
Vildagliptin ICV-STZ mice Improved memory retention and dose-
dependent attenuation of Ab, tau
phosphorylation, and inflammatory markers;
elevated GLP-1 levels
[111]
806 www.drugdiscoverytoday.com
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TABLE 2 (Continued )
Drug Experimental model Results and/or effects Human data Refs
Sitagliptin 7-month-old APP/PSEN1 mice Improved memory impairment in contextual
fear conditioning test; increased brain levels
of GLP-1; reduced inflammation markers;
reduced APP and Ab deposits
[33]
OLETF T2DM rat model Increased tau phosphorylation; increased IRS-
1sP616
[34]
Sprague-Dawley rats Improved working memories; reduced insulin
resistance; increased acetylcholine content of
hypothalamus and Adipo R1 expression
[254]
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inhibitors modulate several events that are of relevance to the
pathogenesis of PD (and AD).
Neuroinflammation
Inflammation is increasingly recognised as a key contributor to the
pathogenesis of PD. Epidemiological studies suggest nonsteroidal
anti-inflammatory drug (NSAID) use confers a decreased risk of
developing PD [37]; positron emission tomography (PET) imaging
of patients with early-stage PD showed significantly increased
microglial activation [38], which could drive neuronal loss in both
PDD and AD [39]; sustained expression of the proinflammatory
cytokine tumour necrosis factor alpha (TNF-a) is associated with
neurodegeneration of dopaminergic neurons [40]; and increased
proinflammatory mediators are seen in the substantia nigra on
postmortem examination [41]. Moreover, genome-wide associa-
tion studies (GWAS) have reported an association between certain
human leucocyte anagen (HLA) alleles and the risk of PD.
GLP-1 analogues and DPP-IV inhibitors have demonstrated
anti-inflammatory properties across a range of experimental mod-
els of PD. Saxagliptin treatment in a rat rotenone model supressed
production of TNF-a, inducible nitric oxide synthase (iNOS), and
myeloperoxidase (MPO) [23]. Similarly, administering exendin-4
to rodents following nigrostriatal lesions induced by LPS and
MPTP toxins prevented toxin-induced microglial activation and
suppressed production of proinflammatory cytokines, including
TNF-a and interleukin (IL)-1B. This was associated with restoration
of extracellular DA and tyrosine hydroxylase (TH) activity, with
subsequent motor and behavioural improvements [17,20]. More
recently, in diabetic rat models, exenatide and liraglutide treat-
ment had antipsychotic, anxiolytic, and antidepressant effects
[42–44], which have been speculated to be due, in part, to its
anti-inflammatory effects [45].
Regulation of microglial activity is thought to have a critical role
in neuroinflammation in PD. While microglial activation might
initially be protective in the initial stages, prolonged activation by
alpha-synuclein, proinflammatory cytokines, and neighbouring
neuronal death [46–49] can lead to polarisation towards the cyto-
toxic M1 phenotype. This can be severely damaging as the disease
progresses [50], leading to a continuous and self-perpetuating
persistent inflammatory environment [51,52], and has been iden-
tified as a major factor in driving dopaminergic degeneration in PD
[39]. Correspondingly, strategies to enhance the cytoprotective
M2 microglial response in models of PD have proven to be neu-
roprotective [53,54], highlighting the importance of microglia
regulation.The ability of GLP-1 analogues to suppress cytotoxic microglial
responses and enhance cytoprotective phenotypes have demon-
strated benefits across a variety of experimental models. GLP-1-
mediated inhibitory effects on microglia have resulted in: reduced
infarct size and neuronal death in models of stroke [55–59];
reversal of cognitive and behavioural impairments in rodent mod-
els of traumatic brain injury (TBI) [60–62]; prevention of hippo-
campal synapse loss in (APP)/presenilin-1 (PSEN1) and
intracerebroventricular (ICV) streptozotocin (STZ) rodent models
of AD [63,64]; reduced circulating monocyte cytokine production
and psoriatic plaque severity in patients with diabetes and psoria-
sis [65], and attenuation of atherosclerotic lesions in arterial walls
in models of myocardial ischaemia/reperfusion injury (reducing
monocyte and/or macrophage accumulation) [66,67].
The underlying mechanism responsible for GLP-1 analogues
modulation of microglial function remains under debate, but
might involve regulation of the transcription factor nuclear factor
(NF)-kB, an important downstream target of the GLP-1R/PI3K/AKT
pathway, which regulates inflammatory gene expression and med-
iates the proinflammatory response of microglial cells. Perhaps not
unsurprisingly, NF-kB has also been implicated in the pathogene-
sis of PD. Increased NF-kB activity is seen in TH+ dopaminergic
neurons and in astrocytes and microglia in the substantia nigra
pars compacta (SNPc) of patients with PD and in animal models
[68]. By contrast, inhibition of NF-kB is neuroprotective in models
of PD [69,70] and retards ageing and increases lifespan in mice
[71]. Saxagliptin and vildagliptin have both been shown to signif-
icantly suppress NF-kB expression (and subsequent proinflamma-
tory cytokine cascades) in a rotenone rodent model of PD [23,72].
Similarly, exendin-4 administration has been shown to inhibit
activation of NF-kB and the resultant inflammatory response in
endothelial cells [73], rodent models of obesity [73,74], and renal
injury [75,76], resulting in improved cell survival. Although ex-
tensive crosstalk exists because various proinflammatory media-
tors can directly activate NF-kB [77], upregulation of the AKT
pathway also upregulates IkBa, a specific endogenous inhibitor
of NF-kB, resulting in reduced neuroinflammation [78], suggesting
a possible mechanism linking GLP-1R activation and inflamma-
tion.
Mitochondrial function and/or oxidative stress
As regulators of cellular energy homeostasis and cell death signal-
ling, the continued integrity of mitochondria within a cell is
crucial for its sustained health. In particular, dopaminergic neu-
rons of the SNPc have characteristically long-range projections
that require a high rate of mitochondrial oxidative metabolismwww.drugdiscoverytoday.com 807
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chondrial function. In parallel, significant evidence suggests that
events that affect mitochondrial function, such as defective mito-
phagy, increased accumulation of mtDNA mutations, defects of
complex I of the respiratory chain, accumulation of alpha-synu-
clein, dysregulated mitochondrial calcium homeostasis, and in-
creased oxidative stress, are all involved in the pathogenesis of PD
and, furthermore, can promote further injury to neighbouring
mitochondria, creating a vicious cycle of further degeneration
[79,80].
GLP-1R activation has demonstrated multiple beneficial actions
on mitochondria across a range of experimental models. Saxaglip-
tin preserved mitochondrial function by elevating complex I and
antiapoptotic protein B-cell lymphoma 2 (Bcl-2) in a rat rotenone
model of PD [23] and geniposide, a novel GLP-1 agonist, upregu-
lated expression of Bcl-2 with subsequent reduced caspase 3 acti-
vation, resulting in preservation of dopaminergic neurons in an
MPTP mouse model of PD [81]. Similarly, exendin-4 has been
shown to increase mitochondrial biogenesis, number, and mass
in rat insulinoma cells [82], and to inhibit the mitochondrial
apoptotic pathway, resulting in functional improvements in rat
models of spinal cord injury [83] and protection of retinal cells in
diabetic rats [84]. In addition, exenatide was able to improve
mitochondrial respiration and suppress the opening of the mito-
chondrial permeability transition pore, resulting in attenuation of
myocardial hypertrophy and oxidative stress-induced injury in
rodent models of myocardial ischaemia, leading to increased
survival rates [85].
Recent studies have suggested how GLP-1R activation influ-
ences mitochondrial function. In a mouse model of amyotrophic
lateral sclerosis (ALS), the neuroprotective effects of exendin-4
treatment were associated with modulation of mitochondrial
intracellular calcium [86] and increased expression of mitofusin-
2 (Mfn2), an endoplasmic reticulum (ER)–mitochondria-tethering
protein that enhances ER–mitochondria coupling [87,88]. This is
particularly relevant because a recent study suggested that alpha-
synuclein causes mitochondrial fragmentation and/or damage by
reducing this ER–mitochondrial connectivity [89].
Growing evidence also implicates the PI3K/AKT pathway as
being partly responsible for the effects of GLP-1R activation on
mitochondria [90]. Activation of GLP-1R causes upregulation of
AKT, leading to inhibition of FOXO1 and reduced production of
proapoptotic proteins (BiM and FAS), while concurrent GLP-1R-
induced elevation of cAMP enhances upregulation of antiapopto-
tic proteins (Bcl-2 and Bcl-XL). Together, these actions contribute
to preserving mitochondrial function by helping stabilise the
outer mitochondrial membrane, preventing efflux of cytochrome
c into the cytoplasm and reducing the activation of caspase 9 and
3, subsequently resulting in reduced apoptosis and oxidative stress
[91–93].
In addition, a recent study highlighted another important
pathway that might be involved in mitochondrial biogenesis.
Exendin-4 administration in pancreatic b cells was associated with
a twofold increase in the expression of peroxisome proliferator-
activated receptor-gamma coactivator 1a (PGC-1a) [82], a master
regulator of mitochondrial biogenesis. Perhaps highlighting the
importance of mitochondrial function in the pathogenesis of
PD, growing evidence implicates dysregulated PGC-1a activity808 www.drugdiscoverytoday.comas playing a critical role in the pathogenesis of PD. GWAS studies
revealed the downregulation of PGC-1a-responsive genes in
patients with early PD [94]; PGC-1a polymorphisms are associated
with increased risk of early-onset PD [95] and in vitro studies
indicate that loss of PGC-1a is associated with increased accumu-
lation of alpha-synuclein [96]. Conversely, overexpression or
activation of PGC-1a protects dopaminergic neurons from
MPTP-induced degeneration in vivo, enhances mitochondrial
biogenesis, and prevents alpha-synuclein-induced dopaminergic
neuronal loss [94].
Importantly, post-translational mechanisms, such as acetyla-
tion and protein phosphorylation, can regulate the activity of
PGC-1a (and hence mitochondrial biogenesis), and can be influ-
enced by genetic and environmental factors.
GLP-1 analogues have not been shown to interact with PGC-1a
directly, but studies suggest that GLP-1R activation can influence
PGC-1a activity indirectly. In models of liver disease, exendin-4
treatment led to upregulation of Sirtuin 1 (SIRT1; an NAD-depen-
dent protein deacetylase and known upstream regulator of PGC-1a
activation) [97,98], which, together with AMPK activation,
resulted in enhanced PGC-1a activity, improvements in mito-
chondrial function, and reduction in ER stress and inflammation
[99,100]. Similar results demonstrated in models of CNS disease
suggest that GLP-1 analogues also modulate the expression of
SIRT1 in neurons. In mice fed a high-fat diet, liraglutide decreased
oxidative stress and inflammation, which was associated with
increased expression of SIRT1 [101]. Encouragingly, studies indi-
cate that SIRT1 overexpression is protective in many cell and
animal models of PD [102]. Similarly, regular exercise, known to
reduce the risk of PD and improve function outcomes in patients
with PD, induces upregulation of SIRT1 and, as a result, increases
PGC-1a activity. In addition, resveratrol, a potent activator of
SIRT1, protects against 3-nitropropanoic acid (3-NP)-induced
motor and behavioural deficits and improved motor function in
mice via increased PGC-1a activity and increased mitochondrial
biogenesis [103,104]. Taken together, there is accumulating evi-
dence linking GLP-1R activation and mitochondrial function.
Protein aggregation
Dysfunction of lysosomal systems, disruption of normal processes
through which cells degrade abnormal proteins and/or cellular
constituents (autophagy), and the aggregation of alpha-synuclein
into toxic fibrils, are thought to be crucial steps in the process
leading to the degeneration of dopaminergic neurons in PD, and
are also implicated in PDD and Dementia with Lewy bodies (DLB).
Recent studies indicate that 50% of patients with PDD also have Ab
plaques and hyperphosphorylated tau-containing neurofibrillary
tangles, which are usually seen in the brains of patients with AD.
Furthermore, Ab is an independent predictor of cognitive decline
in PD [105] and this co-morbid pathology might act synergistically
with Lewy bodies and Lewy neurites to lead to toxic gain of
function and confer a worse prognosis [106–109]. This has led
some to suggest that agents that can influence the development of
AD-related pathology would be beneficial in a subset of patients
with PDD.
In vitro studies show that GLP-1 analogues can alter the cellular
production and accumulation of Ab deposits, reduce Ab-induced
cell death and toxicity and levels of amyloid precursor protein
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neuroblastoma cultures [111]. Similarly, in vivo treatment with
the GLP-1 analogues exenatide, liraglutide and lixisenatide has
been shown to reduce tau hyperphosphorylation [112,113], amy-
loid plaque load, and soluble Ab levels across a range of models of
AD, counteracting their toxic effects and leading to improvements
in memory performance and learning. Data regarding the effects of
DPP-IV inhibitors on AD-related pathology are conflicting: while
saxagliptin, vildagliptin, and sitagliptin were shown to reduce tau
and Ab deposits in ICV STZ and APP/PSEN1 mice models of AD
[34,35,114], in a Otsuka Long-Evans Tokushima fatty (OLETF)
T2DM rat model, sitagliptin paradoxically increased tau phosphor-
ylation, although differences in methodology might account for
these observations [36].
Studies indicate that the effects of GLP-1 analogues on amyloid
aggregation are at least partially due to activation of the PI3K/AKT
pathway, resulting in increased phosphorylation (and inactiva-
tion) of downstream target Glycogen synthase kinase 3 beta (GSK-
3B) [115–117]. GSK-3B is a major kinase involved in promoting
phosphorylation of tau and aggregation of Ab through modula-
tion of APP processing [118] and, correspondingly, inhibition of
GSK-3B activity has been linked with neuroprotection and reduced
AD pathology. GSK-3B is also involved in modulating autophagy,
and dysregulated GSK-3B activity is implicated in PD pathogenesis
and promotion of Lewy body formation [119]. Correspondingly,
studies demonstrate that inhibition of GSK-3B can promote autop-
hagy and halt the expression and aggregation of alpha-synuclein
and its subsequent neurotoxic effects in vitro and in vivo [120,121].
GLP-1R activation-induced upregulation of SIRT1 in neurons
might also contribute to beneficial effects on protein aggregation
[101]. As well as influencing mitochondrial function via modula-
tion of PGC-1a, SIRT1 is also involved in the regulation of autop-
hagy. In models of PD, increased expression of SIRT1 activated
heat shock protein 70 (Hsp70), a molecular chaperone that pro-
motes normal folding of alpha-synuclein. Furthermore, in models
of AD, SIRT1 reduced plaque formation by activation of retinoic
acid receptor b, which activates ADAM10 to facilitate processing of
APP along a nonamyloidogenic pathway, and can directly deace-
tylate tau, enabling ubiquitin ligases to promote its clearance
[102,122,123]. Correspondingly, in experimental models of PD
and AD, compounds that increase SIRT1 expression can reduce
alpha-synuclein aggregation, and Ab and neurofibrillary tau pa-
thology, respectively, resulting in improved behaviour [102].
Recently, geniposide was shown to upregulate expression of
insulin-degrading enzyme (IDE), a zinc-metalloendopeptidase
that can degrade insulin and other small peptides that can form
b-pleated sheets. IDE is activated by PI3K and was recently shown
to inhibit alpha-synuclein fibril formation in vitro by binding to
alpha-synuclein oligomers, blocking them from forming fibres
[127]. IDE can also bind and degrade Ab, halting their neurotoxic
toxic effects [128–130], and recent studies showed that upregula-
tion of IDE by geniposide antagonised cell damage induced by
Ab1–42 exposure in primary cultured cortical neurons [124] and
reduced Ab1–42 levels in diabetic rats [125] (reviewed in [126]).
A recent study also showed that, via an increase in cAMP
response element-binding protein (CREB; a downstream effector
of the PI3K/AKT pathway), exendin-4 caused upregulation of
ADAM10 at the plasma membrane in adult mice, which promoteda nonamyloidogenic APP-processing pathway, potentially repre-
senting another mechanism responsible for reducing levels of Ab
in vivo [131].
Neurogenesis
Neurogenesis continues to occur throughout adulthood in the
subgranular zone of the dentate gyrus in the hippocampus and the
subventricular zone (SVZ) near the lateral ventricle, although its
levels decline with age. These endogenous stem cells can migrate
into the granule cell layer of the dentate gyrus, develop neuronal
markers, and eventually become integrated within local circuits
[132]. In particular, it is thought that the SVZ continually provides
GABA- and DA-containing interneurons for the olfactory bulb.
However, postmortem studies suggest that the age-related decline
in adult neurogenesis is accelerated in patients with PD [133,134],
possibly due to dopaminergic depletion having a negative effect
on cellular proliferation [135,136]. Although the relations are not
entirely understood, altered neurogenesis in the hippocampus in
PD [133] might be linked with impairments not only in memory
processing, but also in olfaction and depression [135,137].
GLP-1R are expressed in the hippocampus and SVZ and exen-
din-4 treatment has been shown not only to stimulate cellular
proliferation in human neuronal cell cultures [138–140], but to
also promote differentiation into more mature neuronal pheno-
types [19,111,138,141]. In experimental models of PD, exendin-4
treatment 1 week after 6-OHDA-induced nigrostriatal degenera-
tion stimulated neurogenesis in the SVZ of the rat brain and
improved dopaminergic markers, leading to functional motor
improvements and normalisation of behaviour [19]. Similarly,
chronic treatment of rodents with exendin-4 enhanced hippo-
campal neurogenesis and led to improvements in reference mem-
ory performance and decreased immobility in the forced swim test,
suggesting improvements in cognitive function and mood disor-
ders [141]. In both studies, these effects persisted weeks after
cessation of treatment, or became apparent only after chronic
administration, suggesting possible neuroregenerative effects.
However, it is unclear whether the reduced TH+ staining seen
in the striatum following initial neurotoxin administration in
these models represents a phenotypical shift in protein expression
rather than cell loss, and whether exendin-4 is able to ‘restore’ the
phenotypic expression as a result of trophic effects rather than to
stimulate the generation of new neurons. In addition, improve-
ments in cognitive performance following liraglutide administra-
tion in rodent models of AD were associated with increases in
hippocampal CA1 neuronal numbers [32,142–144].
How GLP-1R activation influences neurogenesis is unclear, but
studies indicate that activation of the PI3K/AKT pathway is needed
for many of the effects on cellular proliferation and differentiation
[145–148]. Recent studies showed that liraglutide-induced hippo-
campal neurogenesis is accompanied by increased expression of
Mash1, an important regulator of neuronal precursor production
[142,149] that is required for AKT-induced neuronal differentia-
tion [150]. However, because neurogenesis can be stimulated by
diverse factors, such as exercise [151], antidepressants [152], and
neurotrophic factors [153], and is also decreased by ageing, insulin
resistance [154], microglial activation [155], loss of DA neurons
[156], and aggregation of alpha-synuclein [135], it might be rea-
sonable to suggest that activation of GLP-1R indirectly influenceswww.drugdiscoverytoday.com 809
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cesses. For example, the inhibitory effects of exendin-4 on micro-
glial activation were associated with increased stem and/or
progenitor cell proliferation in the SVZ and neuroblast production
in the striatum in a rodent model of stroke [59].
Trophic factors
Trophic factors can influence cell survival and axonal growth and
have the potential to protect degenerating DA neurons as well as to
promote regeneration of the nigrostriatal DA system [157]. There-
fore, the exogenous administration of neurotrophic factors to the
PD midbrain and/or striatum to slow or halt degeneration of
dopaminergic neurons has become a promising active area of
research. However, despite the potential of this method, current
studies have been hampered by the inherent poor ability of trophic
factors to cross the BBB, leading to alternative methods of admin-
istration using viral vectors [158] or intranasal delivery [159] being
explored.
Despite their large molecular size, peripherally administered
GLP-1 analogues can cross the BBB to facilitate trophic factor
expression. Brain-derived neurotrophic factor (BDNF), a trophic
factor that can rescue dopaminergic neurons, reverse synapse loss
after disease onset [160], and promote neural progenitor cell
differentiation and survival, was shown to be upregulated by
intraperitoneal exendin-4 administration in adult mice [131].
Similarly, the neuroprotective effects of saxagliptin in a rotenone
model of PD were accompanied by an increase in striatal BDNF
[23].
Studies show that GLP-1 analogues might also directly act as a
neurotrophic factor. In PC12 cells, exendin-4 exposure induced
neurite outgrowth in a manner similar to nerve growth factor
(NGF) [138,161] and, furthermore, these effects on neurite out-
growth translated to functional improvements in sensory electro-
physiology and behavioural sensory loss in models of diabetic
polyneuropathy [162,163]. Importantly, these studies showed that
GLP-1R activation was able to rescue degenerating cells after NGF-
mediated withdrawal, suggesting independent trophic effects
[164,165]. Furthermore, in different tissue models, pretreatment
with exendin-4 improved the survival, adhesion, and therapeutic
efficacy of transplanted adipose-derived stem cells (ADSCs) in
ischaemic myocardium [166–168] and islet cell transplants [169].
These trophic effects might be mediated by activation of the
AKT pathway and increases in intracellular cAMP, given that BDNF
is a transcriptional target of cAMP response element-binding
protein (CREB), which are both elevated in response to GLP-1R
activation. Similar effects on neurite outgrowth effects are thought
to be mediated via the rise in intracellular cAMP and induction of
the MAPK/ERK pathway, which promotes neuronal survival in
response to nutrient depletion [161,170].
Learning and memory
The clinical phenotype of PD evolves due not only to neurode-
generation, but also to abnormal patterns of firing of intercon-
nected neuronal pathways. Dysfunctional synaptic plasticity has
been implicated in the initial onset of PD [171,172], has relevance
in the development of the motor complications of PD, such
as dyskinesias [172,173], and also might partially contribute to
the complex evolution of cognitive impairment. Dementia is810 www.drugdiscoverytoday.comcommon in the advanced stages of PD, affecting up to 80% of
patients [174], and often heralds impending residential care and
mortality; however, mild cognitive impairment (MCI) can occur in
early stages and a quarter of patients already have evidence of
cognitive deficits at diagnosis [175,176].
Given its role as an integrator of memory formation, alterations
in hippocampal structure and function are implicated in cognitive
decline in PD [177,178], correlate with memory defects and beha-
vioural abnormalities [178,179], and might predict progression to
PDD [180]. GLP-1R-activated signalling appears to be involved
in memory. GLP-1Rs are present in the CA2–CA3 region of the
hippocampus in abundance [181] and studies have shown that
mice lacking GLP-1R have learning deficits and their neurons
display impaired LTP (the cellular correlate of memory formation)
[182]. Conversely, GLP-1 analogue administration in rodents and
rats overexpressing GLP-1R demonstrate improved hippocampal
CA1 LTP and synaptic plasticity, resulting in subsequent improved
spatial learning and memory performance [26,144,183], effects
that were blocked in the presence of a GLP-1R antagonist.
Significant evidence also implicates the cholinergic system
arising from the substantia innominate of the basal forebrain as
having a key role in cognitive decline in PD. Imaging combining
PET with N-[11C]-methyl-4-piperidyl acetate (MP4A) and 18F-
fluorodopa (FDOPA) showed severe cholinergic deficit in temporal
and parietal regions in patients with PDD compared with patients
with PD [184]. In addition, postmortem studies showed that
patients with PDD and AD had lost >90% of neurons in the
nucleus basalis of Meynert (NBM) compared with age-matched
controls, resulting in a cortical cholinergic deficit [185,186]. More
recent in vivo studies using PET and volumetric magnetic reso-
nance imaging (MRI) confirmed that this cortical cholinergic
deficit is greater in patients with PDD (or AD) compared with
controls [187], and correlates to the degree of cognitive im-
pairment [188,189]. Whereas augmentation of these neurotrans-
mitter deficits with rivastigmine, an acetylcholinesterase inhibitor
(and the only licensed treatment for PDD and DLB), has positive
effects on cognition and behavioural disturbance, it can often
worsen motor deficits [190].
GLP-1 analogues can improve the functionality of cholinergic
neurons; exendin-4 was shown to enhance acetylcholine produc-
tion [identified through elevated choline acetyltransferase (ChAT)
activity] in NSC19 cells [165]. Furthermore, in studies using ChAT-
positive immunoreactivity as a marker for cholinergic cell bodies
in vivo, exendin-4 significantly reduced ibotenic acid-induced loss
of cell bodies in NBM cholinergic neurons within the basal fore-
brain in a rat compared with controls, demonstrating its ability to
restore cholinergic marker function following excitotoxic damage
[164].
In conclusion, activation of GLP-1R via GLP-1 analogues or
indirectly via DPP-IV inhibition has a remarkable array of protec-
tive effects on cellular proliferation, differentiation, inflamma-
tion, and mitochondrial function, and also might be associated
with reduced levels of alpha-synuclein and amyloid plaques in the
brain.
Insulin resistance
A growing body of data suggests that T2DM and PD share common
pathological mechanisms. Epidemiological studies suggest that
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ripheral insulin resistance, broadly defined as reduced tissue re-
sponsiveness to insulin, is associated with a more severe clinical
phenotype, accelerated disease progression, and increased risk of
cognitive decline [191]. Furthermore, studies indicate that a pro-
cess analogous to peripheral insulin resistance occurs in the brains
of patients with PD and might be responsible for initiating and/or
exacerbating neurodegeneration (F. Bassil, unpublished data,
2015) [192–195].
Within the CNS, although not directly involved in glucose
uptake, insulin is able to modulate many processes disrupted in
PD, including apoptosis, autophagy, mitochondrial biogenesis,
oxidative stress, neuroinflammation, protein synthesis, alpha-synu-
clein aggregation, and synaptic plasticity [80,196]. These effects are
mainly via activation of two pathways (MAPK/ERK and PI3K/AKT)
and, accordingly, experimental models of insulin resistance dem-
onstrate enhanced nigrostriatal neurodegeneration, accelerated
microglia cell activation, and alpha-synuclein aggregation in both
pancreas and midbrain [197] and altered DA turnover resulting
in enhanced motor deficits, impaired cognition, and behavioural
disorders compared with matched controls [198–201].
The relation between insulin resistance and neurodegeneration
is not limited to PD, and similar links exist in AD, where studies
suggest prolonged metabolic stress and Ab induce production of
proinflammatory cytokines that can phosphorylate and activate
insulin receptor substrate 1 (IRS-1) serine kinases IkB kinase (IKK),
Janus kinase (JNK), and Erk2. In turn, these kinases ultimately
phosphorylate IRS-1 at serine residues, causing inactivation and
inhibition of downstream insulin signalling [202–205].
Although the cause of insulin resistance in PD is still be eluci-
dated, recent studies suggest that alpha-synuclein negatively reg-
ulates insulin signalling in a similar manner. Either through
inhibition of protein phosphatase (PP)2A activity, sustaining
mTORC1 activation, enhancing an insulin-signalling negative
feedback loop, and increasing degradation of IRS-1 [206] or via
alpha-synuclein-induced microglial production of proinflamma-
tory cytokines, leading to activation of IKK or JNK, and ultimately
phosphorylation and inactivation of IRS-1 at serine residues,
thereby sustaining a vicious cycle of aggregation and neurodegen-
eration.
Consequently, because GLP-1R stimulation activates similar
pathways ‘de-activated’ as a consequence of insulin resistance,
some have suggested that it is the ability to restore brain insulin
sensitivity that is responsible for the diverse range of its pleotropic
effects. Exenatide and liraglutide have been shown to reduce levels
of IRS-1pS616 and IRS-1pS36 (putative biomarkers of neuronal
insulin resistance in AD) in the APP/PSEN1 model of AD and
diabetic mice, leading not only to facilitation of insulin signalling,
but also the restoration of normal tissue responses to insulin
[116,207,208], resulting in improvements in AD pathology and
functional improvements in cognition. Similarly, a novel GLP-1R
agonist, geniposide, attenuated insulin deficiency-induced Ab
accumulation in a APP/PSEN1 Tg model of AD [209].
GLP-1Rs are also ubiquitously distributed throughout the body
and, as such, GLP-1R stimulation has an array of systemic effects
that might also be of relevance in regards to limiting neurode-
generation based on reducing insulin resistance. Ageing, obesity
(or rather increased adiposity), and metabolic stress (such asperipheral insulin resistance) are risk factors for PD and contribute
to a state of chronic systemic inflammation [198]. Furthermore,
studies indicate that proinflammatory cytokines can cross the BBB
to directly induce cell death and/or activate IRS serine kinases,
such as JNK, in a similar manner to activated microglia to induce
and/or exacerbate neuronal insulin resistance [210,211].
Weight loss is an effective method in reducing the development
of peripheral insulin resistance and GLP-1 analogues have long-
lasting anorexic effects. The mechanism is uncertain but might
involve increasing energy expenditure [212–214], reducing gastric
emptying, decreasing nutrient absorption, inducing nausea, or
promoting satiety through stimulation of hypocretin and/or
orexin neurons in the lateral hypothalamus [213,215,216], which
ultimately can result in reduced levels of systemic inflammatory
markers (as observed in patients with psoriasis) [65].
As well as driving systemic inflammation, excessive peripheral
adipose tissue can alter lipid composition and function of hippo-
campal synapses [217]. GLP-1 analogues can improve insulin
sensitivity in obese mouse models by directly inhibiting inflam-
matory pathways in adipocytes and, via upregulation of the tran-
scription factor peroxisome proliferator-activated receptor gamma
(PPAR-y), can regulate adipogenesis, promoting preadipocyte pro-
liferation, which reduces apoptosis [74,218,219]. Dysregulation of
ceramides (lipids derived from fatty acid metabolism) is altered in
patients with PD and is associated with worse cognition [220,221].
Studies show that they can cross the BBB to activate microglia,
inducing central inflammation and cell death [222], and also
directly inhibit central insulin signalling leading to enhanced
nigrostriatal degeneration [223]. In addition alterations in their
metabolism are associated with the misfolding and aggregation of
alpha-synuclein [224]. Nonalcoholic steatohepatitis (NASH)
occurs frequently with T2DM and obesity, contributes to periph-
eral insulin resistance, and, via increased endogenous hepatic TNF-
a expression, can increase the production of peripheral ceramides
in adipose tissue. This has been shown to contribute to CNS
oxidative stress, insulin resistance, and neuronal cytoskeletal col-
lapse [223]. Recent studies have shown that exenatide reversed
hepatosteatosis-induced cognitive and behavioural deficits in rats,
which were accompanied by reduced levels of brain TNF-a [225].
These effects were thought to be mediated by increased expression
of SIRT1 and activation of the AMPK pathway, leading to beneficial
effects on mitochondrial function, reduction in ER stress, and
reduced lipogenesis, fat storage, and inflammation [99,100].
Taken together, due to the distribution of GLP-1Rs, stimulation
with analogues or indirectly with DPP-IV inhibitors can lead to
wide-ranging systemic effects on whole-body metabolism, im-
proving peripheral and central insulin resistance.
The AKT pathway
Studies have implicated the involvement of PI3K/ERK/MAPK and
PI3K/AKT-dependent pathways as being important in GLP-1R
activation in terms of diverting signalling away from apoptosis
towards cell survival. Although it difficult to separate the relative
contribution of each pathway because extensive crosstalk exists,
some studies that utilise selective AKT inhibitors suggest that the
AKT pathway is at least partially responsible for the effects of GLP-
1R stimulation on cellular proliferation [226], trophic effects [90],
and antiapoptotic effects [227,228].www.drugdiscoverytoday.com 811
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AKT acts as a master regulator of cellular function [229]. The AKT
pathway has been identified as a central hub that might be
responsible for degenerating dopaminergic neurons in PD
[230,231] and some important downstream effectors, such as
GSK-3B, mTOR, caspase-9, and the transcription factor FOXO1,
have themselves been identified as novel targets for halting neu-
rodegeneration in PD. Substantial evidence suggests that loss of
control of AKT signalling is involved in several age-related dis-
eases, including AD [232], and growing evidence suggests that
altered AKT signalling is also a key component of PD pathogenesis
and influences alpha-synuclein aggregation [233], providing a
possible link between insulin resistance and neurodegeneration
in PD [229,230,233–237]. In parallel, studies using trophic factors
or small molecules to activate AKT appear to slow neurodegenera-
tion in PD [238–240]. However, as with any biological system,
negative feedback control of AKT is essential to maintain optimal
tissue function; for example, although AKT usually inactivates
FOXO, physiological FOXO activity is a critical counterbalance
to allow necessary transcription of stress-response genes and repair
systems [241,242], and studies show that elevated AKT phosphor-
ylation is associated with levodopa (L-DOPA)-induced dyskinesias
in MPTP-treated monkeys [243].
Thus, the protective effects of restoration of insulin signalling
might be due, in part, to an increase in the basal activation of the
AKT pathway, restoring the balance and activating signalling
cascades that ultimately promote cellular survival.
The therapeutic potential of GLP-1R activation
In regards to their potential utility in PD, GLP-1 analogues and
DPP-IV are emerging as promising therapeutic agents in PD,
regardless of whether their useful mechanisms of action in
neurodegeneration are via an insulinotrophic effect, an effect
on IRS-1 phosphorylation, or GLP-1 receptor action on AKT.
However, maximising the translational potential of this ap-
proach is crucial, and significant differences regarding their
pharmacodynamics and pharmacokinetic properties exist be-
tween not only the drug classes, but also compounds of the
same class, which is reflected in variations in their efficacy in
glycaemic control in diabetes. Thus, it might be reasonable to
assume that some might exert greater neuroprotective effects in
PD than others, although current comparable data in PD are
sparse. Studies from diabetic populations suggest that the risk of
inducing hypoglycaemia with either GLP-1 analogues or DPP-IV
inhibitors in a nondiabetic population is low; however, weight
loss and gastrointestinal adverse effects are less common with
DPP-IV inhibitors than with GLP-1 analogues [244], which is
potentially significant if utilising these drugs in older, often frail,
populations.
Although no clinical data yet exist, extrapolating the more
positive results of DPP-IV inhibition seen in animal models to
humans might be difficult: doses of DPP-IV inhibitors used in these
animal models are 10–20 times higher than those used in T2DM
and, as such, the high levels of brain GLP-1 in rats produced by
DPP-IV inhibition might be difficult to reproduce in humans.
Similarly, DPP-IV inhibitors have low penetration of the BBB.
Conversely, GLP-1 analogues, with the exception of dulaglutide,
are all able to penetrate the BBB to some degree in experimental812 www.drugdiscoverytoday.commodels [15,16] and exert central effects in doses comparable to
those in humans [9].
Similarly, data regarding the comparison between individual
GLP-1 analogues in models of PD are limited. Data from diabetic
studies suggest that liraglutide is associated with greater effects on
glucose homeostasis than exenatide, but has greater incidence of
adverse gastrointestinal effects [245], whereas exenatide has been
linked to a small increased risk of pancreatitis in patients with
diabetes (although subsequent meta-analysis has not supported
this link). Few studies have attempted to compare the effects of
GLP-1 analogues in models of PD: a recent study indicated that, in
comparison to liraglutide and lixisenatide, exenatide was unable
to offer protection against MPTP-induced dopaminergic degener-
ation in a mouse model [22] (which could be explained by differ-
ences in equivalent dosing). Similarly, in mice, whereas liraglutide
and lixisenatide were both able to cross the BBB and enhance
neurogenesis in the dentate gyrus, lixisenatide achieved signifi-
cantly higher increases in cAMP compared with liraglutide, and at
lower doses [16].
Data regarding GLP-1 analogues and/or DPP-IV inhibitor
use in clinical trials of PD are limited but encouragingly: exena-
tide exposure in a small, open-label randomised controlled trial
in 45 patients with PD led to a mean advantage of 7.0 points on
the MDS-UPDRS Part III, which persisted after a 12-month
‘wash-out’ period, together with improvements in the Mattis
Dementia Rating scale and well as other non-motor areas
[246,247]. The single-blind design of this trial does not yet
confirm proof of efficacy, but the encouraging results have
prompted conduct of a larger, double-blind trial using a once-
weekly, long-acting form of exenatide in moderate-stage PD,
with results expected in May 2016 (Clinicaltrials.gov identifier
NCT01971242).
In parallel, encouraging results from an double-blind random-
ised controlled trial assessing the effects of liraglutide on cerebral
amyloid deposits in patients with AD have recently been reported,
suggesting that liraglutide treatment halted decline of the cerebral
glucose metabolism compared with controls. This hints at an
ability of liraglutide to stabilise energy metabolism in areas of
the brain that have been shown to correlate with cognitive decline
in patients with AD [248]. Similar trials evaluating GLP-1 analo-
gues in AD are ongoing: a Phase II trial evaluating exenatide in 230
patients with AD or MCI (NCT01255163) is currently underway
and a randomised placebo-controlled Phase II trial assessing the
safety and efficacy of liraglutide in 206 patients with early AD
(NCT018430755) is continuing.
In terms of future directions, although the current crop of GLP-
1 analogues (exenatide, liraglutide, and lixisenatide) are effective
in reducing insulin resistance, newer molecules, such as unim-
olecular dual GLP-1/glucose-dependent insulinotrophic polypep-
tide (GIP) agonists or triple GLP-1/GIP/glucagon receptor
agonists, have been shown to have superior efficacy in reducing
peripheral insulin resistance compared with conventional
‘mono’ GLP-1 agonists [249,250] with additional benefits of
reduction of adverse gastrointestinal effects. A novel dual GLP-
1/GIP receptor agonist was recently shown to attenuate dopami-
nergic cell death in an MPTP mouse model of PD [251] and these
newer agents might also deserve to have their potential effects
explored in PD.
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GLP-1R stimulation is associated with an impressive array of
positive actions that are relevant to PD pathogenesis, such as
enhancing mitochondrial biogenesis, suppressing microglial acti-
vation and inflammation, enhancing autophagy, and clearance of
aggregated proteins, and it is probably that it is this combination
of actions that accounts for its positive effects in models of not
only PD, but also AD, Huntington’s disease, TBI, and ALS.
Further research will clarify whether insulin resistance is a cause
or consequence of neurodegeneration in PD, but, if confirmed, this
might offer clinicians a useful window to try to identify high-risk
individuals (e.g. those with metabolic syndrome or other genetic
risk factors) and offer appropriate measures to slow this process
(and thus neurodegeneration).
It is also becoming increasing clear that the pathophysiology of
PD is not confined to a limited range of organs or cell systems, but
is rather a system-wide disorder, with complex interplay between
peripheral and central organs. This is supported by evidence of
systemic dysregulated metabolism in patients often years before
motor symptoms become apparent, which more importantly can
impact the course of degeneration within the CNS, suggesting a
common pathological signalling system and/or axis (such as a
ligand–receptor axis) present centrally and peripherally, which,
when disrupted by an initiating factor, leads to system-wide
pathophysiological disruption. This implies that a suitable agent
might be able to modulate and restore these dysregulated networksin a whole-body approach, which by its nature is more efficient
and likely to be more successful than an agent specially targeting
one aspect of the neurodegenerative pathway [252].
Given its expression in a variety of tissues throughout the body
and involvement in mediating systemic and peripheral inflamma-
tion, metabolic homeostasis, gut–brain signalling, cardiovascular
activity, and circadian rhythms [253], GLP-1/GLP1R has been
proposed as a likely candidate for one of the ligand–receptor
signalling axes exerting multiple effects in PD [252]. Therefore,
GLP-1R activation by agonists could explain the range of systemic
and neuroprotective effects of GLP-1 stimulation seen in models of
PD.
In future, research is focus on developing nonpeptidergic li-
gands that can modify the activity of the GLP-1R itself, which,
theoretically, would be able to exert more potent effects on GLP-1R
at multiple levels, thus maximising their effects. Although some
novel compounds have been developed with evidence of efficacy
at increasing cAMP and insulin potentiation [254,255], further
research will be needed to ascertain whether maximising exploi-
tation of this newly discovered signalling axis would offer greater
benefits in the treatment of neurodegenerative diseases.
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